Sep 2026· New England Journal of Medicine· Vol 395, pp. 1166-1179· 3 citations· ⚡ 2 influential· 19 references
Medicine
TL;DR
Over a period of 12 weeks, oveporexton significantly improved measures of wakefulness, sleepiness, and cataplexy in participants with narcolepsy type 1.
Abstract
Background
Narcolepsy type 1 is characterized by excessive daytime sleepiness, cataplexy, disrupted sleep, sleep paralysis, and hypnagogic or hypnopompic hallucinations. Oveporexton (TAK-861), an oral orexin receptor 2-selective agonist, reduced symptoms of narcolepsy type 1 in a previous phase 2 trial.
Methods
We conducted two phase 3, randomized, placebo-controlled trials evaluating the efficacy and safety of oveporexton over a period of 12 weeks. Participants 16 to 70 years of age with narcolepsy type 1 were randomly assigned in a 3:3:2 ratio to receive twice-daily oveporexton (1 mg or 2 mg) or placebo in the First Light trial and in a 2:1 ratio to receive twice-daily oveporexton (2 mg) or placebo in the Radiant Light trial. The primary end point was the change from baseline to week 12 in mean sleep latency (the ability to stay awake under soporific conditions) on the Maintenance of Wakefulness Test (MWT; range, 0 to 40 minutes; normal, ≥20). Key secondary end points included the change from baseline to week 12 in the Epworth Sleepiness Scale (ESS) total score (range, 0 to 24; normal, <10) and the weekly cataplexy rate at week 12.
Results
A total of 168 participants were enrolled in the First Light trial and 105 in the Radiant Light trial. Mean changes from baseline to week 12 in mean sleep latency on the MWT ranged from 14.3 to 19.8 minutes with oveporexton, as compared with -0.4 to -0.8 minutes with placebo (adjusted P<0.001 for all comparisons vs. placebo). Mean changes in the ESS total score ranged from -9.7 to -11.8 with oveporexton, as compared with -1.5 to -1.7 with placebo (adjusted P<0.001 for all comparisons vs. placebo). Median percent reductions in the weekly cataplexy rate ranged from 79.0 to 88.8% with oveporexton, as compared with 27.7 to 39.1% with placebo (adjusted P<0.001 for all comparisons vs. placebo). Adverse events occurred in 86 to 89% of the participants with oveporexton, as compared with 43 to 54% with placebo; the most common adverse events were increased urinary frequency and transient insomnia, which occurred in a majority of participants receiving oveporexton.
Conclusions
Over a period of 12 weeks, oveporexton significantly improved measures of wakefulness, sleepiness, and cataplexy in participants with narcolepsy type 1. Increased urinary frequency and transient insomnia were common side effects. (Funded by Takeda Development Center Americas; the First Light and Radiant Light ClinicalTrials.gov numbers, NCT06470828 and NCT06505031.).
Oveporexton, a selective oral orexin-2 receptor agonist, represents a targeted therapeutic approach for narcolepsy type 1 (NT1). Phase 2 and 3 trials demonstrate significant improvements in wakefulness, excessive daytime sleepiness, and cataplexy, alongside potential cognitive benefits. However, available data are limi...
Aashan Ahmad, R. Abbas, Joshua Ekouo et al.· Annals of Medicine and Surge...· 0 citations
Background/Objectives: Narcolepsy type 1 (NT1) results from loss of hypothalamic orexin neurons. Selective orexin-2 receptor (OX2R) agonists now permit direct receptor-level restoration of deficient signaling, but recent broad reviews do not fully integrate the post-approval, trial-specific efficacy, prescribing, and s...
Yahya A. Alzahrani, M. Harbi· Journal of Clinical Medicine· 0 citations
Sodium oxybate significantly reduces EDS in narcolepsy with consistent effects across formulations and once-nightly and low-sodium formulations offer additional benefits in terms of dosing convenience and reduced sodium burden.
Preeti Kanawjia, S. Kanaujia, Renu Kumari· DARU Journal of Pharmaceutic...· 0 citations
Attention-Deficit/Hyperactivity Disorder (ADHD) is a highly prevalent neurodevelopmental disorder affecting both pediatric and adult populations. Stimulant medications (STM) including methylphenidate (MPH) or lisdexamfetamine (LDX) are recommended as first-line treatment for ADHD symptoms, although evidence regar...
K. Mammeri, S. Weibel, E. Rüfenacht et al.· BMC Psychiatry· 0 citations
Sleep disruption is common in Alzheimer's disease (AD). Diphenhydramine (DPH), a first-generation antihistamine with anticholinergic properties, is widely used as an over-the-counter sleep aid. We tested whether chronic DPH treatment alters sleep architecture in 5XFAD and wild-type female mice. Female 5XFAD (n = 16) an...
M. Copeland, D. Youngstrom, Kathryn S. Konrad et al.· Neurobiology of Sleep and Ci...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.